SCHEMBL2908472

SCHEMBL2908472

CS(=O)(=O)C1Cc2cc(Cl)ccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 3/20 0.52
SIGMAR1 Q99720 2/20 0.41
S100A4 P26447 2/20 0.41
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
HTR2B P41595 2/20 0.40
HTR1A P08908 3/20 0.39
HTR7 P34969 3/20 0.39
DRD3 P35462 2/20 0.39
DRD2 P14416 1/20 0.39
HRH1 P35367 1/20 0.39
CYP11B2 P19099 1/20 0.39
SRD5A1 P18405 3/20 0.38
ACHE P22303 2/20 0.36
DRD4 P21917 2/20 0.36
SRD5A2 P31213 2/20 0.36
CES1 P23141 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276920 0.80 METAP1 (0.44) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL8170903 0.77 ACHE (0.56) METAP1ACHECES1
SCHEMBL29404958 0.77 METAP1 (0.56) METAP1SIGMAR1HTR2AHTR2CHTR2B
SCHEMBL6248819 0.77 METAP1 (0.56) METAP1SIGMAR1HTR2AHTR2CHTR2B
SCHEMBL7590593 0.75 METAP1 (0.54) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL30666697 0.74 METAP1 (0.53) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL27317325 0.74 METAP1 (0.53) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL31208446 0.74 METAP1 (0.53) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL27346204 0.74 METAP1 (0.53) METAP1SIGMAR1S100A4HTR2AHTR2C
SCHEMBL11563001 0.74 METAP1 (0.53) METAP1SIGMAR1S100A4HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425000-B1 USE OF POLYSUBSTITUTED INDAN-1-OL SYSTEMS FOR PRODUCING DRUGS USED IN THE PROPHYLAXIS OR TREATMENT OF OBESITY SANOFI AVENTIS DEUTSCHLAND (DE) 2012-08-01 EP disclosed
EP-1423358-B1 POLYSUBSTITUTED INDAN-1-OL SYSTEMS, METHOD FOR THE PRODUCTION AND USE THEREOF AS DRUGS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-04 EP disclosed
US-7763662-B2 Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-07-27 US disclosed
EP-1423359-B1 C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-14 EP disclosed
EP-1425267-B1 C2-SUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-06-30 EP disclosed
EP-1425266-B1 C2-SUBSTITUTED INDANE-1-OLS AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-04-22 EP disclosed
EP-1425264-B1 C2-DISUBSTITUTED INDANE-1-OL SYSTEMS AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-10-29 EP disclosed
EP-1425265-B1 DERIVATIVES OF C2-SUBSTITUTED INDAN-1-OL SYSTEMS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-10-22 EP disclosed
EP-1424985-B1 USE OF DERIVATIVES OF C2-SUBSTITUTED INDANE-1-OL SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR THE TREATMENT OF OBESITY SANOFI AVENTIS DEUTSCHLAND (DE) 2008-02-13 EP disclosed
US-7081467-B2 C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-07-25 US disclosed
WO-2003020677-A2 C2-SUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020697-A1 C2-DISUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020255-A1 USE OF POLYSUBSTITUTED INDAN-1-OL SYSTEMS FOR PRODUCING DRUGS USED IN THE PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020256-A1 USE OF C2-SUBSTITUTED INDANE-1-ONE SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020695-A1 C2-DISUBSTITUTED INDANE-1-OL SYSTEMS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020263-A1 USE OF C2-SUBSTITUTED INDANE-1-OL SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020696-A1 C2-SUBSTITUTED INDANE-1-OLS AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020199-A1 USE OF DERIVATIVES OF C2-SUBSTITUTED INDAN-1-OL SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR THE TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2003020694-A1 DERIVATIVES OF C2-SUBSTITUTED INDAN-1-OL SYSTEMS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-13 WO disclosed
WO-2002019971-A1 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS JENAPHARM GMBH & CO. KG (DE) 2002-03-14 WO disclosed